http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-PA05001055-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fc6c2e9e63b6561f2f46b1de31f6379 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10 |
| filingDate | 2003-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1ab58df270c6b89a615d7800744c74e |
| publicationDate | 2005-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-PA05001055-A |
| titleOfInvention | COMPOSITION FOR PROLONGED RELEASE COMPRESSED UNDERSTANDING A DOPAMINE RECEIVER AGONIST. |
| abstract | A prolonged-release pharmaceutical composition in the form of an orally administrable tablet comprises as active pharmaceutical agent a compound of formula (1): or a pharmaceutically acceptable salt thereof, in which: R1, R2 and R3 are the same or different and are H, C1-6 alkyl (optionally substituted phenyl), C3-5 alkenyl or alkynyl or C3-10 cycloalkyl, or in which R3 is as indicated above and R1 and R2 are cyclized with the atom of N attached to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups; X is H, F, C1, Br, 1, OH, C1-6 alkyl or alkoxy, CN, carboxamide, carboxyl or (C1-6 alkyl) carbonyl; A is CH, CH2, CHF, CHCI, CHBr, CHI, CHCH3, C = O, CS, CSCH3, CNH, CNH2 CNHCH3, CNHCOOCH3, CNHCN, SO2 or N; B is CH, CHZ, CH2, CHCI, CHBr, CHI, C = O, N, NH or NCH3 and n is O or 1; and D is CH, CH2, CHE, CHCI, CHBr, CHI, C = O, O, N, NH or NCH3 the agent is dispersed in a matrix comprising a hydrophilic polymer and a starch having a resistance to breakage. at least about 0.15 kN cm-2 at a solid fraction representative of the tablet; The composition exhibits effective prolonged release properties for the treatment of Parkinson's disease; the tablet is optionally coated; The tablets of the invention have improved resistance to wear or erosion during processing, packaging and handling. |
| priorityDate | 2002-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.